Human Heparin Binding EGF-like Growth Factor (AF)

Source: Genetically modified E.coli.
Predicted MW: Monomer, 9.9 kDa (87 aa)
Heparin-binding EGF-like growth factor (HB-EGF) is a member of the epidermal growth factor (EGF) family and is expressed by monocytes and macrophages. HB-EGF is the predominant growth factor involved in epithelialization during wound healing. HB-EGF signals through the receptor tyrosine kinase ErbB2 to maintain adult heart homeostasis, and promotes cardiac valve development through binding in high affinity to the epidermal growth factor receptor (EGFR). HB-EGF binds the the ErbB4 receptor tyrosine kinase to mediate implantation of the human blastocyst. HB-EGF also functions as a potent mitogen for fibroblasts and smooth muscle cells.

Endotoxin: Less than 0.1 ng/µg (1 IEU/µg) as determined by LAL test.
Biological Activity was determined by3T3 cell proliferation at <=1 ng/mL; >= 1.0 x 10^6 units/mg . Centrifuge vial before opening, Suspend the product by gently pipetting the above recommended solution down the sides of the vial. DO NOT VORTEX. Allow several minutes for complete reconstitution. For prolonged storage, dilute to working aliquots in a 0.1% BSA solution, store at -80°C and avoid repeat freeze thaws. Upon reconstitution, a small amount of visible precipitate can be expected. A 10% overfill has been added to the total material vialed to compensate for this loss.

For Research Use Only. Not for use in diagnostic/therapeutics procedures.

Subcellular location:	Cell membrane
Post transnational modification:	O-glycosylated with core 1 or possibly core 8 glycans. Thr-47 is a minor glycosylation site compared to Thr-44.
BioGrid:	108172. 9 interactions.

There are currently no product reviews Write a review on this product!